Anebulo Pharmaceuticals (ANEB) AI Stock Analysis

• Market Cap: $43.14M
• Dividend Yield: N/A
• Average Volume (3M): 16.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: N/A
• EPS Growth: 23.10%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 41,084,732
• 10 Day Avg. Volume: 7,376
• 30 Day Avg. Volume: 16,982
• PEG Ratio: 0.26
• Price to Book (P/B): 4.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.67
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -4.05
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-11.50% Downside)

The score is primarily weighed down by pre-revenue financials with ongoing losses and cash burn, plus technically weak price momentum (below key moving averages with negative MACD). A debt-free balance sheet and a modest buyback provide partial support, but valuation signals are limited by a negative P/E and no dividend data.

Positive Factors

Debt-free balance sheet

Anebulo’s lack of debt materially lowers financial risk and reduces mandatory cash outflows for interest, preserving scarce cash for R&D. For a clinical-stage biotech, a debt-free structure extends strategic flexibility for licensing, partnerships, or timed financings over the next several quarters.

Management executing go-private strategy

The board’s shift from an expensive reverse split to a self-tender shows pragmatic governance and active capital structure management. Executing a clear path to delist can reduce ongoing public reporting costs and allow management to prioritize long-term clinical development without short-term market pressures.

Oversubscribed tender reflects shareholder engagement

Strong tender participation at a cash premium suggests investor willingness to transact and supports management’s ability to implement strategic transactions. That execution capability helps streamline the shareholder base and can simplify governance as the company focuses on advancing clinical programs.

Negative Factors

Pre-revenue with persistent cash burn

ANEB remains pre-revenue and consistently consumes cash to fund operations and trials. Negative operating and free cash flow create continual reliance on external financing; absent material capital raises or partnerships, funding constraints could slow clinical progress and milestone delivery over the coming months.

Declining shareholders' equity

The meaningful drop in equity reflects accumulated losses and weaker net worth, reducing the balance-sheet cushion to absorb further R&D spend. A shrinking equity base can limit borrowing or partnership leverage and may force more dilutive financings, increasing execution risk for long-term development plans.

Very limited operational team

With only two employees, internal capacity to run trials, manage regulatory interactions, and scale clinical operations is constrained. The company will likely depend heavily on CROs and partners, which increases coordination risk, external cost exposure, and potential delays in meeting development milestones over the medium term.

Anebulo Pharmaceuticals Business Overview & Revenue Model

Company Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

How the Company Makes Money

Anebulo Pharmaceuticals generates revenue primarily through the development and potential commercialization of its lead product candidate, ANEB-001. As a clinical-stage company, Anebulo's current revenue streams are limited, and it largely relies on funding through public and private investment to support its research and development activities. In the future, the company plans to earn income through licensing agreements, strategic partnerships, and sales of its pharmaceutical products upon receiving regulatory approval. Significant partnerships with larger pharmaceutical companies could also contribute to its revenue by providing milestone payments, royalties, and collaborative research funding.

Anebulo Pharmaceuticals Financial Statement Overview

Summary

Early-stage profile with $0 revenue, persistent net losses, and ongoing negative free cash flow (TTM FCF about -$5.9M). A key offset is a debt-free balance sheet, but equity has declined over time, highlighting reliance on external funding.

Income Statement

ANEB is still pre-revenue, with $0 revenue in both TTM (Trailing-Twelve-Months) and the last several annual periods, so profitability is entirely driven by operating spend. Losses remain significant (TTM net loss of about $8.4M; annual net losses generally in the ~$6.8M–$11.7M range), with no clear, sustained improvement trend. A modest positive is that recent losses are below the 2023 peak, but the business has not yet demonstrated a path to revenue or earnings leverage.

Balance Sheet

The balance sheet is conservatively positioned with no debt reported, which materially lowers financial risk. However, equity has declined meaningfully from 2022 to 2025 (from ~$15.1M to ~$9.7M TTM), reflecting ongoing losses and cash consumption, and returns on equity are consistently negative. Overall: strong leverage profile (no debt), but weakening net worth over time.

Cash Flow

Cash generation is weak, with negative operating cash flow and negative free cash flow in every period shown. TTM (Trailing-Twelve-Months) free cash flow is roughly -$5.9M, and while burn appears lower than 2023–2024 (a relative improvement), the company is still funding operations through its balance sheet rather than internal cash generation. Free cash flow growth is volatile, underscoring an uneven spending/burn pattern typical of early-stage biotech but still a clear liquidity risk if capital is not replenished.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-8.10M	-8.10M	-7.79M	-11.73M	-6.83M	-30.24M
Net Income	-8.44M	-8.48M	-8.20M	-11.73M	-6.83M	-30.25M
Balance Sheet
Total Assets	10.70M	12.15M	4.07M	11.67M	15.58M	21.65M
Cash, Cash Equivalents and Short-Term Investments	10.35M	11.63M	3.09M	11.25M	14.55M	19.99M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	963.82K	487.69K	260.58K	1.07M	512.53K	241.63K
Stockholders Equity	9.74M	11.66M	3.81M	10.60M	15.07M	21.41M
Cash Flow
Free Cash Flow	-5.93M	-6.35M	-8.09M	-9.68M	-5.44M	-4.87M
Operating Cash Flow	-5.93M	-6.35M	-8.09M	-9.68M	-5.44M	-4.87M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	14.88M	14.88M	-62.35K	6.38M	0.00	21.83M

Anebulo Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANEB, the sentiment is Negative. The current price of 1.13 is above the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.65, and below the 200-day MA of 1.89, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 39.37 is Neutral, neither overbought nor oversold. The STOCH value of 39.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANEB.

Anebulo Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANRO	56 Neutral	$480.91M	-6.73	-45.01%	―	―	-7.87%
CNTX	52 Neutral	$239.80M	―	-33.68%	―	―	69.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRZN	50 Neutral	$184.67M	-0.99	―	―	-63.96%	-28.50%
VTGN	46 Neutral	$22.05M	―	―	―	-33.00%	54.91%
ANEB	45 Neutral	$43.14M	-4.46	-145.11%	―	―	23.10%
BYSI	43 Neutral	$63.33M	―	―	―	―	―

Anebulo Pharmaceuticals Corporate Events

Anebulo Pharmaceuticals Completes Oversubscribed Share Repurchase Tender

On January 29, 2026, Anebulo Pharmaceuticals reported the final results of its voluntary self-tender offer, which expired on January 26, 2026, to repurchase up to 300,000 shares of common stock at $3.50 per share. The offer was heavily oversubscribed, with 4,907,881 shares validly tendered and not withdrawn; Anebulo ultimately bought the full 300,000-share maximum, including 134,306 odd-lot shares accepted in full, at an aggregate cost of about $1.05 million, representing approximately 0.73% of shares outstanding as of January 26, 2026. The shares, other than odd lots, were accepted on a pro rata basis using a final proration factor of 3.47392%, and payment in cash without interest will be made promptly to participating shareholders. Management said the transaction met its goal of offering smaller shareholders a chance to exit at a significant premium to market while modestly shrinking the shareholder base, a move that could streamline the company’s investor roster without materially affecting its capital structure.

The most recent analyst rating on (ANEB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.

Anebulo Pharmaceuticals Announces Oversubscribed Self-Tender Offer Results

On January 27, 2026, Anebulo Pharmaceuticals reported preliminary results from its voluntary self-tender offer for up to 300,000 shares of its common stock at $3.50 per share in cash, following the offer’s expiration on January 26, 2026. The offer was significantly oversubscribed, with about 4.9 million shares properly tendered, leading the company to expect pro rata acceptance of approximately 300,000 shares—about 0.73% of shares outstanding as of January 26—at an estimated aggregate cost of $1.05 million, excluding fees and expenses. A preliminary proration factor of roughly 3.5% is expected, with “odd lot” tenders to be accepted in full; final share counts and proration will be confirmed after the guaranteed delivery period, and accepted shares will be paid for in cash while unpurchased shares will be returned promptly. The oversubscription suggests robust shareholder interest in the liquidity event and will result in a modest reduction in Anebulo’s share count, with limited but targeted impact on capital allocation and ownership structure.

The most recent analyst rating on (ANEB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.

Anebulo Pharmaceuticals Launches Self-Tender Offer to Go Private

On December 22, 2025, Anebulo Pharmaceuticals announced that its board had abandoned a previously proposed large reverse stock split and related special shareholder meeting in favor of launching a voluntary self-tender offer as part of its plan to go private. The company intends to commence a cash tender offer to buy up to 300,000 shares of its common stock at $3.50 per share, for a total of up to $1.05 million, a move aimed at keeping its shareholder count below 300, the threshold needed to complete its going-private transaction. The board concluded that the reverse split had become too costly after certain investors distributed holdings across multiple small accounts to maximize fractional share payouts, significantly increasing the projected expense of that strategy. By shifting to the self-tender approach, Anebulo is seeking a more economically efficient path to delisting and deregistration while retaining the option to revisit a reverse split or other structural transaction in the future if conditions change.

The most recent analyst rating on (ANEB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.